![Stefan Kraft](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Mr. Stefan Kraft is a Head of Transaction Management, Risk Controlling & Fund Reporting at Medical Strategy GmbH.
He formerly worked at Epsilon Verlagsmarketing GmbH.
Mr. Kraft has a Masters's in Economics from the Ludwig-Maximilians-University, and also studied Erasmus-Studies as a Part of the Study Path at Charles-University.
Actieve functies van Stefan Kraft
| Bedrijven | Functie | Begin |
|---|---|---|
Medical Strategy GmbH
 Medical Strategy GmbH Investment ManagersFinance MS is an active growth-oriented investor and manages portfolios invested in global equity with a long-term outlook. The firm focuses on mid- and small-cap companies from the healthcare sector, including pharma, emerging pharma, biotech, genomics, medtech, drug delivery and e-health. MS uses computer models to continuously screen a selection of 700-800 listed companies as well as pre-IPOs for which they systematically collect data in a proprietary database. This information is completed by both in-house and third-party fundamental research | Analyst-Equity | 01-01-2010 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
9
Eerstegraads connecties
1
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
Medical Strategy GmbH
Medical Strategy GmbH Investment ManagersFinance MS is an active growth-oriented investor and manages portfolios invested in global equity with a long-term outlook. The firm focuses on mid- and small-cap companies from the healthcare sector, including pharma, emerging pharma, biotech, genomics, medtech, drug delivery and e-health. MS uses computer models to continuously screen a selection of 700-800 listed companies as well as pre-IPOs for which they systematically collect data in a proprietary database. This information is completed by both in-house and third-party fundamental research | Finance |
